Patients with CML in the lymphoid blastic phase have inferior response to anti‐CD19 CAR T‐cell therapy compared to de novo Ph‐positive B cell acute lymphoblastic leukemia

• Mei‐Jing Liu,
• Kai‐Wen Tan,
• Han‐Yu Cao,
• Si‐Man Huang,
• Chong‐Sheng Qian,
• Sheng‐Li Xue,
• Hai‐Ping Dai,
• Wen‐Jie Gong

Affiliations

Mei‐Jing Liu

National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China

Kai‐Wen Tan

National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China

Han‐Yu Cao

National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China

Si‐Man Huang

National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China

Chong‐Sheng Qian

National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China

Sheng‐Li Xue

National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China

Hai‐Ping Dai

National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China

Wen‐Jie Gong

National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou People's Republic of China